Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization (2015 - 2023)

Spyre Therapeutics (SYRE) has 9 years of Accumulated Depreciation & Amortization data on file, last reported at $744000.0 in Q4 2023.

• For the quarter ending Q4 2023, Accumulated Depreciation & Amortization fell 52.52% year-over-year to $744000.0; the trailing twelve-month figure through Dec 2023 stood at $744000.0 (down 52.52% YoY), and the FY2023 full-year result was $744000.0, down 52.52% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2023 stood at $744000.0, down from $1.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $2.0 million in Q4 2020 and bottomed at $744000.0 in Q4 2023.
• The 5-year median for Accumulated Depreciation & Amortization is $1.6 million (2022), against an average of $1.4 million.
• The widest annual swing landed in 2020, when Accumulated Depreciation & Amortization jumped 87.96%; it then slumped 52.52% in 2023.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then retreated by 20.52% to $1.6 million in 2021, then declined by 0.57% to $1.6 million in 2022, then plunged by 52.52% to $744000.0 in 2023.
• The last three Accumulated Depreciation & Amortization figures came in at $744000.0 (Q4 2023), $1.6 million (Q4 2022), and $1.6 million (Q4 2021), per Business Quant data.

Peer Comparison